The real snag will come in the next decade: The U.S. represents 50% of group sales for Novo, and while there is a “good ...

The Danish drugmaker has gone from steady to chaotic. Its fight with Pfizer to acquire Metsera is getting more heated.

Novo Nordisk A/S downgraded after Q3 earnings and weight loss sector risks. Explore valuation, partnerships, and market ...

COPENHAGEN (Reuters) -Shares in Novo Nordisk rose in early trade on Monday, after the Wegovy-maker on Saturday dropped its ...

Novo Nordisk has partnered with Emcure Pharmaceuticals to bring Poviztra, their latest weight-loss medication, to the Indian market. This collaboration builds on Novo Nordisk's prior success with ...

Eli Lilly and Novo Nordisk are cutting prices for popular weight-loss drugs in deals struck with the Trump administration, ...

Novo Nordisk reports Wegovy users lost 21% body weight and saw improved heart health markers, as EMA and FDA reviews near for ...

Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn ...

Despite all that, there are some good reasons to consider buying into Novo Nordisk -- and the best is its low valuation, ...

Novo Nordisk and Emcure Pharma team up to bring Poviztra, a new weight loss injection, to India. Learn more about this latest ...

Under the agreement, Emcure Pharma will be the exclusive distributor responsible for the commercialisation and marketing of ...

As part of the agreement, Emcure Pharma will be the exclusive distributor responsible for the commercialisation and marketing of Poviztra in India.